Document is current
Any future updates will be listed below
-
Authors
Springfeld, Christoph
Hackert, Thilo https://orcid.org/0000-0002-7012-1196
Palmer, Daniel H. https://orcid.org/0000-0002-7147-5703
Öhlund, Daniel
Peccerella, Teresa
Hank, Thomas
Büchler, Markus W.
Michalski, Christoph W.
Neoptolemos, John P. https://orcid.org/0000-0002-6201-7399
- License Information
-
More Information
Article History
Received: 16 July 2025
Revised: 21 October 2025
Accepted: 14 November 2025
First Online: 4 December 2025
Competing interests
: CS declares advisory board membership for Astra Zeneca, Bayer, BMS, Roche, Incyte, MSD, Revolution Medicines, Servier and Taiho. DHP declares advisory board membership and consultancy for MSD, BMS, AZ, Sirtex, Taiho, Jazz, Viatris, Nucana, Medannex, Servier, and Pfizer; Research Grant Funding from BMS, Sirtex, Nucana, and Medannex. JPN declares advisory board membership for BioNTech (BNT32), and the patent 52378-704.601 PCT 23 May 2025, Combination of Irinotecan and AP-001 for treating cancer. T. Hackert, DÖ, TP, T. Hank, MWB and CWM declare no competing interests.
: All of the authors approved the final manuscript for publication.
